Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Belsomra Most Promoted Drug for 2 Months on End: Anterio Ranking
October 21, 2015
- Development of Osteoporosis Drugs in Homestretch, Odanacatib’s US Filing Expected by Year-End
October 21, 2015
- Shift to Specialty – 2: Santen Invests in the Future Over Present Profits
October 21, 2015
- Kowa Seeks Japan Approval of Livalo Successor Pemafibrate
October 20, 2015
- Daiichi Sankyo to Shed 1,000 Jobs in US
October 20, 2015
- Shift to Specialty - 1: Drug Makers Urged to Retool Strategies amid Govt Pressure, Dismal Biz Environment
October 19, 2015
- Eisai, Ajinomoto Link Arms to Create Leading Specialty Pharma for GI Disease
October 16, 2015
- MSD Files Allergy Drug Desloratadine in Japan
October 16, 2015
- Eisai’s GI Disease Biz to Integrate with Ajinomoto Pharma
October 15, 2015
- Plavix Retains Top Slot in FY2014 Japan Drug Sales Ranking: Jiho Tally
October 14, 2015
- Toyama Chemical Licenses RA Drug to Turkish Firm
October 14, 2015
- Astellas Gains Worldwide Rights to Next-Gen DNA Vaccines
October 13, 2015
- (PRESS RELEASE) Shionogi to Spin Off Consumer Healthcare Biz Next Year
October 13, 2015
- Eisai’s Thyroid Cancer Drug Lenvima Approved in S. Korea
October 13, 2015
- AZ Begins Japan PI Trial of CTLA-4 Inhibitor for Malignant Mesothelioma
October 9, 2015
- Ethical Drug Sales Surge 9.0% in August: Crecon Report
October 8, 2015
- Meiji Seika Pharma Commences Long-Term Studies of Safinamide
October 8, 2015
- Merck Lauds Nobel Medicine Prize Winners Omura, Campbell
October 7, 2015
- GreenPeptide Files IND in US for Cancer Peptide Vaccine
October 7, 2015
- Anti-Obesity Effect of Rare Sugar D-Psicose Confirmed: Matsutani Chemical Industry
October 7, 2015
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…